|
|
 | | | |
- close
- close
- close
- close
Amicus Therapeutics Inc (FOLD) |
StreetInsider.com
Mar 12
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Amicus+Therapeutics%2C+Inc.+%28FOLD%29+Posts+Q4+Loss+of+20cShare/8178562.html for the full story.
Forbes
Mar 7
Comment
There are two gay marriage cases being argued before the Supreme Court at the end of the month. You can get most of the amicus briefs on Hollingsworth v Perry, which concerns whether the 14th Amendment prevents California from defining marriage...
Benzinga
Mar 4
Comment
Amicus Therapeutics
(Nasdaq: FOLD), today introduced Chaperone-Advanced Replacement Therapy
(CHART™) as the brand name for its technology platform that combines unique
pharmacological chaperones with enzyme replacement therapy (ERT) for...
New York Times
Feb 26
Comment
Dozens of prominent Republicans signed an amicus brief that will be submitted to the Supreme Court ahead of arguments in two cases next month.
TheStreet.com
Feb 19
Comment
CRANBURY, NJ (TheStreet) -- Amicus Therapeutics presented an alternative theory Friday to explain the failure of its Fabry disease drug Amigal in a late-stage clinical trial. Not surprisingly, investors reacted with skepticism and Amicus shares...
StreetInsider.com
Feb 15
Comment
Logmein, Inc. (Nasdaq: LOGM) 29.3% LOWER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $37 million versus the consensus estimate of $36.73 million. Sees Q113 EPS of $0.09-$0.10,...
StreetInsider.com
Feb 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amicus+Therapeutics+%28FOLD%29+Ticks+Lower+on+Following+Study+Results+/8105691.html for the full story.
Benzinga
Feb 15
Comment
Amicus
Therapeutics (Nasdaq: FOLD), today announced additional 6-month (Stage 1)
results from the first ongoing Phase 3 global registration study (Study 011)
of investigational oral migalastat HCl monotherapy (150 mg, every-other-day)
in males and...
Benzinga
Feb 14
Comment
Amicus
Therapeutics (Nasdaq: FOLD) today announced positive results from clinical and
preclinical studies of the pharmacological chaperone AT2220 (duvoglustat HCl)
in combination with ERT for Pompe disease at the Lysosomal Disease Network
WORLD...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
